← 홈

방광·요로상피

3개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3개
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 50%임상시험 152상태 ACTIVE
ADCSFDAFDABiologicAstellasvedotin plus pembrolizumab …Approved

enfortumab vedotin (Padcev)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Renal Pelvis and Ureter Urothelial Carci

#RenalPelvisandUreterUrothelialCa#ADC#Approved#FDA승인#인기+5
효능 ORR 44%임상시험 84상태 RECRUITING
CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 55%임상시험 10상태 APPROVED